Results from two MD Anderson studies demonstrated the significance of combination therapy in follicular lymphoma and chronic lymphoblastic leukemia , two blood cancers that often result in relapse after first treatments. Initial findings for both will be presented this weekend at the 61st American Society of Hematology Annual Meeting & Exposition (ASH).
Abstract 125: Results of a phase II study of obinutuzumab in combination...
MD Anderson’s adoptive cell therapy (ACT) platform is advancing the next generation of cell-based immune therapies to bring innovative approaches...
November is Lung Cancer Awareness Month, and the third Thursday of each November is designated by the American Cancer Society as the Great...
Each year in the U.S., more than 50,000 people will be diagnosed with pancreatic cancer, which ranks around the 10th most common cancer type. However, it is the third leading cause of cancer death, behind only lung and colorectal cancers.
For Pancreatic Cancer Awareness Month, Cancer Frontline spoke with Anirban Maitra, M.B.B.S., scientific director of the Sheikh Ahmed Pancreatic Cancer Research Center, about important ongoing...
MD Anderson researchers have identified early genomic events that may lead to malignant transformation. They’ve found that tissue adjacent...
Combining two types of immune checkpoint inhibitor fires up responses in T cells that are separate from those initiated by the two drugs individually...
The recent outbreak of lung injury and death associated with e-cigarettes and vaping has led to a renewed scrutiny of electronic nicotine...
Despite major recent advances in oncology drug discovery, including the development of innovative targeted, immune and cell-based therapies...
Combining a 3D virtual cutting guide with a surgical navigation tool allowed MD Anderson surgeons to perform a complicated pelvic reconstruction...
Cancer’s ability to evolve in response to treatment and develop resistance to available therapies is one of the most significant challenges...